Creating the global leader in Rare Diseases
Q1 Results 2016
Shire is the global leader in rare diseases
An innovative rare disease-focused biotechnology company committed to differentiated and high patient-impact medicines;
Focused on 7 core therapeutic areas;
Well diversified portfolio with a focus on biologics and products to treat rare conditions that frequently impact children and young adults
Global research, clinical, regulatory, manufacturing, and commercial capabilities enabling us to develop and sell products in over 100 countries, world-wide.
Continuing to deliver strong results while investing in
Product Sales
Strong double digit sales growth; 46% non GAAP EBITDA margin maintained;
VYVANSE, LIALDA, CINRYZE and FIRAZYR all continuing to deliver strong growth, driven by increased volumes;
New product launches GATTEX and NATPARA performing well.
Continuing to deliver strong results while investing in
Non GAAP EPS ADS
Lifitegrast PDUFA date July 22, 2016;
Positive results in adolescents safety and efficacy trial for SHP465;
SHP643 (DX2930) Phase 3 studies enrolling.
Our approach to driving innovation and long-term growth
Sustain
Ensure leadership over time through LCM, Commercial Excellence and strong defense of Intellectual Property.
Build
Deepen and strengthen existing categories by developing and acquiring new assets.
Expand
Broaden footprint into new categories with high potential and that fit our model.
Delivery of strong Non GAAP EBITDA margins in Q1 2016
Royalties and Other Revenues
Contact Us
Start Over